clinical trial · NCT07446400
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
Otsuka Pharmaceutical Development & Commercialization, Inc.·phase1·recruiting·n = 48
Healthy VolunteersRepinatrabitEE/NEMetforminRosuvastatinMethotrexateCarbamazepine
brief summary
The purpose of this study is to assess the drug-drug interaction (DDI) of repinatrabit with ethinyl estradiol/norethindrone or norethisterone (EE/NE), metformin, rosuvastatin, carbamazepine, and methotrexate in healthy participants.
started
Mar 31, 2026
primary completion
Jun 9, 2026
completion
Jun 15, 2026
last updated
May 6, 2026
official title
A Phase 1, 4-arm, Open-label, Drug-drug Interaction Trial to Evaluate the Pharmacokinetics of Repinatrabit Oral Tablets When Co-administered With Ethinyl Estradiol/Norethindrone, Metformin, Carbamazepine, Rosuvastatin, and Methotrexate in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol